Cabozantinib with novolumab and .or ipilipumab for leiomyosarcoam – pro
A randomized trial published in 202 (Van Tine et al) built on previous findings that demonstrated activity as well as an acceptable safety profile. ” The combination of C+I/N was superior to C for the treatment of non-translocation STS for DCR and PFS. Most frequent responding histology was LMS. Correlative work is ongoing.” Another abstract showed that he addition of nivolumab (Opdivo) and ipilimumab (Yervoy) to cabozantinib (Cabometyx) led to an improvement in disease control rate (DCR) and progression-free survival (PFS) vs cabozantinib alone in patients with metastatic soft tissue sarcoma, according to data from a phase 2 trial (NCT04551430) presented at the 2023 ASCO Annual Meeting.
As such this is still E/I treatment.
Brian Andrew Van Tine, Vanessa Eulo, Jacqui Toeniskoetter, Tyler Ruff, Jingqin Luo, Lindsey Kemp, Cristiam Moreno Tellez, Show All , and Breelyn A. Wilky,Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma. Journal of Clinical Oncology
Volume 41, Number 17_suppl
Cabozantinib Plus Nivolumab/Ipilimumab Improves PFS, DCR in Metastatic Soft Tissue Sarcoma. https://www.onclive.com/view/cabozantinib-plus-nivolumab-ipilimumab-generates-pfs-and-dcr-in-metastatic-soft-tissue-sarcoma
NCCN Soft tissue sarcoma 2025